Looking forward to Association for Molecular Pathology’s meeting! Join Labcorp , @PGDx and I for a free workshop, “Liquid Biopsy – Improving Patient Access to Precision Oncology Through Centralized Services and Decentralized Kitted Solutions.” Register here: bit.ly/3yLCwpy. #AMPath22 #AMPlifier

Scientific innovation is required to develop better therapeutic options for patients with #ovariancancer. Led by Shree Bose from Duke University School of Medicine, we explored metabolic biosensors in models to understand changes within the tumor microenvironment. bit.ly/3NoGOcI

Great turn out today at our Association for Molecular Pathology workshop today Association for Molecular Pathology. We reviewed how a simple blood draw from a patient with cancer can become genomic data and inform #precisiononcology. pgdx Labcorp #AMPath22 #AMPlifier

Check out poster #ST028 Association for Molecular Pathology today. @PGDx presents their validation study on plasma focus, an #NGS assay designed for solid tumor profiling from cfDNA. This assay reports SNVs/indels for 33 genes, amplifications in 8 genes, gene fusions in 5 genes and MSI. #AMPath22 #AMPlifier

We performed CGP on 3288 samples using @OmniSeqInsight’s NGS assay. We identified 16 NRG1 fusions – with an incidence of 0.4%. RNA sequencing increases the detection rate for NRG1 fusions and offers therapy options for patients. Visit our Labcorp poster #AMPath22 #AMPlifier

NTRK breakpoints are difficult to detect due to intron size and partner variety. We performed #CGP on 6730 samples with @OmniSeqInsight’s NGS assay and identified 17 NTRK fusions (NTRK1=6, NTRK2=3, NTRK3=8) in multiple tumor types. Visit our Labcorp poster #AMPath22 #AMPlifier

Getting ready for the #ASH22 meeting with my #ASHaiku: ASH workshop with me December 10th, New Orleans Hemepath with Labcorp ASH

Thanks to everyone who attended our Labcorp Case Study presentation where we reviewed the clinical, morphologic, cytogenetic, and #molecular characteristics of a case with a TP53 biallelic alteration. #ASH22 ASH

Grant Hogg presents real-work analysis of 10,283 samples to evaluate impact of #genomic data on #MDS prognosis. About 50% of samples from patients with MDS had molecular findings that stratified clinical risk. #precisiononcology #ASH22 ASH